Keywords
Hepatology
Hepatitis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective:To analyze the characteristics of Autoimmune Hepatitis (AIH). Bibliographic review: AIH is an inflammatory liver disease caused by environmental factors in genetically predisposed patients. It is a chronic T-cell-mediated inflammatory liver disease that affects all ages and is characterized by female preponderance, elevated serum levels of transaminase and immunoglobulin G, positive circulating autoantibodies, and the presence of interface hepatitis on liver histology. It is a disease of unknown etiology, which, if left untreated, can progress to liver cirrhosis and liver failure, with a small (1-2% per year) but significant risk of developing hepatocellular carcinoma. Final considerations: Autoimmune hepatitis is an often fatal disease if not diagnosed and treated early. This is characterized by the progressive destruction of the parenchyma and the development of chronic fibrosis. The goal of treatment in AIH is to achieve complete biochemical and histological remission and prevent the progression of hepatic fibrosis. Immunosuppressive treatment with corticosteroids usually has a good effect and is the most important drug for inducing remission. Azathioprine, with or without corticosteroids, is the main drug to maintain remission.
References
BERETTA-PICCOLI BT, et al. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol, 2017; 23(33): 6030-6048.
BERETTA-PICCOLI BT, et al. Autoimmmune hepatitis. Cell Mol Immunol, 2022; 19(2): 158-176.
BISCHOFF S, et al. Autoimmune Hepatitis: a Review of Established and Evolving Treatments. J Gastrointestin Liver Dis, 2020; 29(3): 429-443.
BOZWARD AG, et al. Autoimmune Hepatitis: Tolerogenic Immunological State During Pregnancy and Immune Escape in Post-partum. Front Immunol, 2020; 11: 591380.
CHRISTEN U, HINTERMANN E. Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease? Front Immunol, 2018; 9: 163.
CHRISTEN U, HINTERMANN E. Pathogens and autoimmune hepatitis. Clin Exp Immunol, 2019; 195(1): 35-51.
COVELLI C, et al. Pathology of autoimmune hepatitis. Pathologica, 2021; 113(3): 185-193.
CZAJA AJ. Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Front Immunol, 2022; 13: 921765.
DONG Y, et al. Ultrasound findings in autoimmune hepatitis. World J Gastroenterol, 2018; 24(15): 1583-1590.
DUCAZU O, et al. Diagnostic and prognostic scoring systems for autoimmune hepatitis: a review. Acta Gastroenterol Belg, 2021; 84(3): 487-495.
GADOUR E. Autoimmune Hepatitis: Treatment Options and Management Review. Cureus, 2021; 13(6): e15682.
HIGUCHI T, et al. Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response. Hum Genomics, 2021; 15(1): 6.
HONG JK, et al. Autoimmune hepatitis triggered by COVID-19. Intern Med J, 2021; 51(7): 1182-1183.
LAMMERT C, et al. Environmental risk factors are associated with autoimmune hepatitis. Liver Int, 2021; 41(10): 2396-2403.
LONGHI MS, et al. Regulatory T cells in autoimmune hepatitis: an updated overview. J Autoimmun, 2021; 119: 102619.
LOTFY A, et al. Stem cell therapies for autoimmune hepatitis. Stem Cell Res Ther. 2021; 12(1): 386.
LOWE D, JOHN S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol, 2018; 10(12): 911-923.
MONTACER KE, et al. Autoimmune hepatitis following acute severe Epstein-Barr virus hepatitis. Pan Afr Med J, 2020; 37: 77.
PAPE S, et al. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019; 7(9): 1156-1163.
SEBODE M, et al. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol, 2018; 9: 609.
SIRBE C, et al. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci, 2021; 22(24): 13578.
STIRNIMANN G, et al. Recurrent and De Novo Autoimmune Hepatitis. Liver Transpl, 2019; 25(1): 152-166.
TAKAHASHI A, OHIRA H. Autoimmune hepatitis, fatty liver, and Fukushima. Fukushima J Med Sci, 2019; 65(2): 25-29.
TANAKA A. Autoimmune Hepatitis: 2019 Update. Gut Liver, 2020; 14(4): 430-438.
THEOCHARIDOU E, HENEGHAN MA. Current and future perspectives in autoimmune hepatitis. Br J Hosp Med (Lond), 2018; 79(3): 151-159.
VESTERHUS M, et al. Diagnosis and treatment of autoimmune hepatitis. Tidsskr Nor Laegeforen, 2021; 141(10): 1-8.
VUERICH M, et al. Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies. Front Immunol, 2021; 12: 746436.
WANG G, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int, 2021; 15(2): 223-257.